Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare autoimmune and kidney-related diseases. They generate revenue primarily through the sale of their flagship product, LUPKYNIS, which is used to treat lupus nephritis. Founded in 1993 and headquartered in Victoria, British Columbia, Aurinia has a rich history of research and development, including significant milestones such as FDA approval for LUPKYNIS in 2021. The company is committed to advancing innovative treatments to improve patient outcomes in underserved medical conditions.

Recent Posts by Aurinia Pharmaceuticals

1-20 of 63